A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-368 Plus Tilsotolimod and Other Therapy Combinations in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
The main objective of this study is to assess safety, tolerability, and pharmacokinetics (PK) of ABBV-368 plus tilsotolimod; ABBV-368 plus tilsotolimod and nab-paclitaxel; and ABBV-368 plus tilsotolimod, nab-paclitaxel, and ABBV-181 in participants with recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC).
Advanced Solid Tumors Cancer
DRUG: ABBV-368|DRUG: Tilsotolimod|DRUG: Nab-paclitaxel|DRUG: ABBV-181
Number of Participants with Adverse Events (AEs), An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment. The investigator assesses the relationship of each event to the use of study., Up to approximately 2 years following the first dose|Change in Vital Signs, Number of participants with clinically significant change from baseline in vital signs like systolic and diastolic blood pressure will be reported., Up to approximately 2 years following the first dose|Change in Clinical Laboratory Test Results, Number of participants with clinically significant change from baseline in clinical laboratory test results like hematology will be reported., Up to approximately 2 years following the first dose|Maximum Observed Serum Concentration (Cmax) of ABBV-368, Maximum Serum Concentration (Cmax) of ABBV-368, Cycle 1 through Cycle 3 (each cycle is approximately 28 days)|Time to Maximum Serum Concentration (Tmax) of ABBV-368, Time to Maximum Serum Concentration (Tmax) of ABBV-368, Cycle 1 through Cycle 3 (each cycle is approximately 28 days)|Area Under Serum Concentration-Time Curve of ABBV-368 From Time 0 to the Time of Last Measurable Concentration (AUCt), Area Under Serum Concentration-Time Curve of ABBV-368 From Time 0 to the Time of Last Measurable Concentration (AUCt), Cycle 1 through Cycle 3 (each cycle is approximately 28 days)|Terminal-Phase Elimination Rate Constant (β) of ABBV-368, Terminal-Phase Elimination Rate Constant (β) of ABBV-368, Cycle 1 through Cycle 3 (each cycle is approximately 28 days)|Terminal Half-Life (t1/2) of ABBV-368, Terminal Half-Life (t1/2) of ABBV-368, Cycle 1 through Cycle 3 (each cycle is approximately 28 days)|Maximum Plasma Concentration (Cmax) of Tilsotolimod, Maximum Observed Plasma Concentration (Cmax) of Tilsotolimod, Cycle 1 through Cycle 3 (each cycle is approximately 28 days)|Time to Maximum Plasma Concentration (Tmax) of Tilsotolimod, Time to Maximum Plasma Concentration (Tmax) of Tilsotolimod, Cycle 1 through Cycle 3 (each cycle is approximately 28 days)|Area Under Plasma Concentration-Time Curve of Tilsotolimod From Time 0 to the Time of Last Measurable Concentration (AUCt), Area Under Plasma Concentration-Time Curve of Tilsotolimod From Time 0 to the Time of Last Measurable Concentration (AUCt), Cycle 1 through Cycle 3 (each cycle is approximately 28 days)|Terminal-Phase Elimination Rate Constant (β) of Tilsotolimod, Terminal-Phase Elimination Rate Constant (β) of Tilsotolimod, Cycle 1 through Cycle 3 (each cycle is approximately 28 days)|Terminal Half-Life (t1/2) of Tilsotolimod, Terminal Half-Life (t1/2) of Tilsotolimod, Cycle 1 through Cycle 3 (each cycle is approximately 28 days)|Maximum Observed Serum Concentration (Cmax) of ABBV-181 (Arm 3 Only), Maximum Observed Serum Concentration (Cmax) of ABBV-181, Cycle 1 through Cycle 3 (each cycle is approximately 28 days)|Time to Maximum Serum Concentration (Tmax) of ABBV-181 (Arm 3 Only), Time to Maximum Serum Concentration (Tmax) of ABBV-181, Cycle 1 through Cycle 3 (each cycle is approximately 28 days)|Area Under Serum Concentration-Time Curve of ABBV-181 From Time 0 to the Time of Last Measurable Concentration (AUCt) (Arm 3 Only), Area Under Serum Concentration-Time Curve of ABBV-181 From Time 0 to the Time of Last Measurable Concentration (AUCt), Cycle 1 through Cycle 3 (each cycle is approximately 28 days)|Terminal-Phase Elimination Rate Constant (β) of ABBV-181 (Arm 3 Only), Terminal-Phase Elimination Rate Constant (β) of ABBV-181, Cycle 1 through Cycle 3 (each cycle is approximately 28 days)|Terminal Half-Life (t1/2) of ABBV-181 (Arm 3 Only), Terminal Half-Life (t1/2) of ABBV-181, Cycle 1 through Cycle 3 (each cycle is approximately 28 days)
Objective Response Rate (ORR), ORR is measured as the percentage of participants with a complete response (CR) or partial response (PR) as a confirmed response., Up to approximately 2 years following the first dose|Clinical Benefit Rate (CBR), CBR is measured as the percentage of participants with a confirmed complete response (CR), confirmed partial response (PR), or stable disease (SD), Up to approximately 2 years following the first dose|Time to Response (TTR), TTR is the time from date of first study drug exposure to the first instance of a complete response (CR) or partial response (PR) as a confirmed response, whichever occurs first., Up to approximately 2 years following the first dose|Progression Free Survival (PFS), PFS is the time from date of first study drug exposure to disease progression or death, whichever occurs first., Up to approximately 2 years following the first dose|Duration of Response (DOR), DOR is the time from the participant's initial response (CR or PR as a confirmed response) to disease progression or death, whichever occurs first., Up to approximately 2 years following the first dose
The main objective of this study is to assess safety, tolerability, and pharmacokinetics (PK) of ABBV-368 plus tilsotolimod; ABBV-368 plus tilsotolimod and nab-paclitaxel; and ABBV-368 plus tilsotolimod, nab-paclitaxel, and ABBV-181 in participants with recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC).